Weight-Loss Pill Approval Highlights Important Role of PCPs
The FDA approved a new weight-loss pill, Foundayo, on April 1, offering an alternative to the existing oral Wegovy. Foundayo can be taken at any time and on an empty stomach, making it more convenient than Wegovy, which has specific timing restrictions. The approval of both drugs highlights the rapid development in the weight-loss medication market and the complexities that primary care practitioners face when prescribing these treatments.
- ▪Foundayo is the second FDA-approved pill for obesity treatment, approved on April 1.
- ▪Unlike Wegovy, Foundayo can be taken without timing restrictions related to meals.
- ▪Both drugs require patients to reduce caloric intake and increase physical activity for optimal results.
Opening excerpt (first ~120 words) tap to expand
A second pill to treat obesity was approved on April 1 by the FDA, heralding a new era in the fight against obesity and overweight.The new drug, Foundayo, is more convenient to take than oral Wegovy, the only other FDA-approved pill for weight loss. Unlike oral Wegovy, Foundayo can be taken on an empty stomach, at any time of the day, and without having to wait at least 30 minutes before eating. Lilly, the maker of Foundayo, reported an average weight loss of 11% of BMI, while Novo Nordisk, which makes oral Wegovy, reported a 16% average weight loss at the highest dose.Patients and their providers will have a choice of pills — and that means more details to pay attention to and new payment and insurance considerations.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
